Research and Development

Bayer Schering Pharma will shortly begin phase III tests of its investigational compound regorafenib for patients with metastatic colorectal cancer.  …

Merck has acquired an exclusive license for a new cancer drug that’s in trials for a number of different forms …

Dutch human gene therapy company Amsterdam Molecular Therapeutics has appointed Professor Sander van Deventer to its supervisory board. One of …

Boehringer Ingelheim and US biotech company Micromet are to research and develop a new BiTE antibody to treat multiple myeloma. …

Leading contract research organisations (CROs) reported a mixed bag of financial results for the first three months of 2010, although …

AstraZeneca and the Global Alliance for TB Drug Development are to collaborate on the discovery and development of drugs to treat tuberculosis.The two …

Sanofi-Aventis has signed an agreement with Indian firm Glenmark Pharmaceuticals to develop novel agents for the treatment of chronic pain. …

A new pharma-academia project being managed by the University of Dundee is setting its sights on improving the effectiveness of …

Bristol-Myers Squibb has been kept on tenterhooks by US regulator the FDA over the future of its investigational kidney transplant …

Glenn Kerkhof, Chiltern CEO, congratulated Kim Todd, Chiltern’s Silver Medal Award Winner in the category of experienced Clinical Research Associate/Site …

Our round-up of developments in the contract research sector includes a new $41m contract for BioFocus, new locations for PPD, …

Evotec is to receive funding of up to 1.5 million euros from a German government fund to advance its H3 …

Merck & Co has partially split the joint roles of chairman, chief executive and president currently held by Richard Clark, …

Novo Nordisk says its diabetes treatment showed “significant” benefits over Merck’s rival Januvia in a head-to-head trial. Results published in …

Oslo-based oncology company Algeta has added Judith Hemberger and Kapil Dhingra to its board of directors. Judith Hemberger has more …